Session Chair Profile
BSc (Hons), Senior Director Compliance, Scientist.com
Biography
Heading a cross industry team, Matt has led the development of a human biospecimen acquisition platform (COMPLI) that helps researchers quickly acquire the human samples they need for their research projects, but also ensures that all biosamples are treated in an ethically compliant way that respects the wishes of the sample donor. COMPLI establishes a rigorous compliance and governance framework that increases visibility, traceability and control for commercial and academic sources of human biospecimens. He has worked in the pharmaceutical industry for 16 years. For 15 years he worked within AstraZeneca (AZ), spending 12 years as a senior scientist working in R&D Genetics and Personalised Healthcare & Biomarkers. Then moving to Procurement to become the Global Category Manager for Human Biological Samples (HBS). Within this role he implemented a new category strategy that transformed the compliance, visibility, traceability and accessibility to HBS for scientists across the global AZ geographic footprint.
Talk
New Standard for Procuring Human Biospecimens
One of the biggest hurdles in pharmaceutical research is the acquisition of human biospecimens. With thousands of global providers, it’s become difficult for researchers to find high-quality samples that have been acquired in an ethically-compliant manner. This talk introduces a new way to address those risks and challenges.
Session Abstract – PMWC 2017 Silicon Valley
Session Synopsis: Pharma’s define the acquisition of human biospecimens as a very high-risk sourcing activity. This session looks at the risks and challenges, from an industry perspective, of acquiring samples and introduces a solution to remove the barriers, administrative burden, and reduce the cost for both Pharma’s and providers of samples.
